Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | KHK | P50053 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | PKM | P14618 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MASP2 | O00187 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7857823 | 0.78 | ALDH1A1 (0.58) | NPSR1ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL8162770 | 0.78 | ALDH1A1 (0.48) | NPSR1ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL31601676 | 0.78 | ALDH1A1 (0.48) | NPSR1ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL147097 | 0.76 | PKM (0.59) | ALDH1A1KDM4ENPC1RAB9APKM | |
| Trifluoroacetic Acid SCHEMBL8515314 | 0.75 | CHRM1 (0.48) | NPSR1ALDH1A1KDM4EKHKNPC1 | |
| SCHEMBL20239570 | 0.75 | NPSR1 (0.47) | NPSR1ALDH1A1KDM4EKHKNPC1 | |
| SCHEMBL18400238 | 0.75 | ALDH1A1 (0.54) | NPSR1ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL1748039 | 0.75 | NPC1 (0.54) | NPSR1ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL9629621 | 0.75 | ALDH1A1 (0.54) | NPSR1ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL29745123 | 0.75 | NPC1 (0.54) | NPSR1ALDH1A1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117534620-A | Preparation method of palladium-catalyzed hydrocarbon bond functionalized 2-trifluoromethyl benzimidazole compound | 六盘水师范学院 | 2024-02-09 | — | — | CN | claimed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-7723526-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723527-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7705149-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705143-B2 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-[1,4]diazepan-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA N.V. (BG) | 2010-04-27 | — | — | US | disclosed |
| US-20090270613-A1 | Benzoimidazole compounds | EDWARDS JAMES P | 2009-10-29 | — | — | US | disclosed |
| US-20090270611-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
| US-20090264646-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264645-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | DUNFORD PAUL J | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270613-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | NPSR1 441/4885ALDH1A1 3379/4885KDM4E 1377/4885 |
| US-20090264646-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | NPSR1 441/4885ALDH1A1 3379/4885KDM4E 1377/4885 |
| US-20090270611-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | NPSR1 441/4885ALDH1A1 3379/4885KDM4E 1377/4885 |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | HRH4, HRH3, BRD4 | NPSR1 497/4885ALDH1A1 2810/4885KDM4E 826/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | NPSR1 1793/4885ALDH1A1 236/4885KDM4E 366/4885 |
| US-20090264645-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | NPSR1 441/4885ALDH1A1 3379/4885KDM4E 1377/4885 |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | HRH4, HRH2, HRH3 | NPSR1 119/4885ALDH1A1 2882/4885KDM4E 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.